

Date: 2018/05/17

To: Federal Communications Commission,
Authorization & Evaluation Division,
7435 Oakland Mills Road,
Columbia, MD 21046

Re: Medical Evolution Kft
FCC ID: 2APPN-MAPALPHA
Confidentiality Request

Gentlemen:

This letter is to comply with 47 CFR 0.457 and 0.459 pertaining to confidentiality material. Medical Evolution Kft requests that the following documents regarding this submission for FCC ID: 2APPN-MAPALPHA be kept confidential:

Exhibit Type	File Name
Block Diagram	Block Diagram.pdf
Schematics	Schematic.pdf
Operational Description	Operational description.pdf
Part list	BOM.pdf

Those documents contain detailed system and equipment description and related information about the product which Medical Evolution Kft considers to be confidential proprietary, a custom design and, otherwise, not releasable to the general public. Since this design is a basis form which future technological products will evolve, Medical Evolution Kft considers this information would be of benefit to its competitors, and that the disclosure of the information in these documents would give competitors an unfair advantage in the market.

Yours Sincerely,



Attila Jakab
Managing Director
Medical Evolution Kft

Date: 2018/05/17

To: Federal Communications Commission,
Authorization & Evaluation Division,
7435 Oakland Mills Road,
Columbia, MD 21046

To Whom It May Concern:

The Medical Evolution Kft the undersigned, hereby authorizes **Mrs. Ivy Zhu from Shenzhen Morlab Communications Technology Co., Ltd.**, to act on the behalf of the Medical Evolution Kft solely in matters relating to the application for an FCC equipment authorization for FCC ID: 2APPN-MAPALPHA including the signing of documents in connection with this Application. Necessary acts carried out **Shenzhen Morlab Communications Technology Co., Ltd.** on our behalf of the Medical Evolution Kft in connection with the Application shall have the same effect as acts of the Medical Evolution Kft. Medical Evolution Kft also hereby certify that no party to this application is subject to a denial of benefits, including FCC benefits, pursuant to Section 5301 of the Anti-Drug Abuse Act of 1988, 21 U.S.C. 862.

Thank you for your attention to this matter.

Yours Sincerely,
Signatory:



Contact name: Attila Jakab
Title: Managing Director
Tel: 0036-70-3979797
Email: attila.jakab@medicalevolution.hu
Company name: Medical Evolution Kft